β-Lactam antibiotics, β-lactamases and bacterial resistance

Bulletin de l'Institut Pasteur

Volumn 96, Issue 3, 1998, Pages 139-150

  Kotra, L P ^a   Mobashery, Shahriar ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Antibiotic; Resistance; Review; Lactam; Lactamase

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; IMIPENEM; ISOENZYME; MONOBACTAM; PENICILLIN BINDING PROTEIN; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULBACTAM; SULTAMICILLIN; TAZOBACTAM; TICARCILLIN; TIMENTIN; UNCLASSIFIED DRUG; ZOCYN;

ANTIBIOTIC RESISTANCE; BACTERIUM; ENZYME ACTIVITY; EVOLUTION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; REVIEW;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA;

EID: 0032126203     PISSN: 00202452     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-2452(98)80009-2     Document Type: Review

References (61)

1. [1] Levy, S. B. (1997), Antibiotic resistance: An ecological imbalance, in "Antibiotic resistance: Origins, evolution, selection and spread" (D. J. Chadwick & J. Goode) (pp 1-14), Ciba Foundation Symposium 207, Wiley, Chichester.
2. [2] Massova, I. & Mobashery, S. (1997), Molecular bases for interactions between β-lactam and β-lactamases. Acc. Chem, Res., 30, 162-168.
3. [3] Bush, K., Jacoby, G.A. & Medeiros, A.A. (1995), A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother., 39, 1211-1233.
4. [4] Medeiros, A.A. (1997), Evolution and dissemination of β-lactamases accelerated by generation of β-lactam antibiotics. Clin. Infect. Dis., 24, S19-S45.
5. [5] Massova, I. & Mobashery, S. (1998), Kinship and diversification of bacterial penicillin-binding proteins and β-lactamases. Antimicrob. Agents Chemother., 42, 1-17.
6. [6] Matagne, A., Lamotte-Brasseur, J. & Frére, J.-M. (1998), Catalytic properties of class A β-lactamases: Efficiency and diversity. Biochem. J., 330, 581-598.
7. [7] Fleming, A. (1929), On the antibacterial action of cultures of a penicillin with special reference to their use in the isolation of B. influenzae. Brit. J. Exp. Pathol., 10, 226-236.
8. [8] Sheehan, J.C. (1982), "The Enchanted ring - the untold story of penicillin." The MIT Press, Cambridge, Massachusetts.
9. [9] Chain, E., Florey, H.W., Gardner, A.D., Heatley, N.G., Jennings, M.A., Orr-Ewing, J. & Sanders, A.G. (1940), Penicillin as chemotherapeutic agent. Lancet, 2, 226-228.
10. [10] Welch, H. & Lewis, C.N. (1951), "Antibiotic Therapy", Chapter III. The Arunde Press, Inc., Washington, D.C.
11. [11] Kirby, W.M.M. (1944), Extraction of a highly potent penicillin inactivator from penicillin resistant staphylococci. Science, 99, 452-453.
12. [12] Barber, M. & Whitehead, J.E.M. (1949), Bacteriophage types in penicillin-resistant staphylococci infection. Brit. Med. J., 2, 565-569.
13. [13] Bush, K. (1997), The evolution of β-lactamases, in "Antibiotic resistance: Origins, evolution, selection and spread" (D.J. Chadwick & J. Goode) (pp. 152-166). Ciba Foundation Symposium 207, Wiley, Chichester.
14. [14] Datta, N. & Kontomichalou, P. (1965), Penicillinase synthesis controlled by infectious R factors in enterobacteriaceae. Nature, 208, 239-241.
15. [15] Bush, K. & Jacoby, G. (1997), Nomenclature of TEM β-lactamases. J. Antimicrob. Chemother., 39, 1-3. Also, the TEM β-lactamases are listed at the web-site, http://www.lahey.org/studies/ webt.htm
16. [16] Ghuysen, J.-M., Charlier, P., Coyette, J., Duez, C., Fonzé, E., Fraipont, C., Goffin, C., Joris, B. & Nguyen-Distéche, M. (1996), Penicillin and beyond: evolution, protein fold, multimodular polypeptides, and multiprotein complexes. Microb. Drug Resist., 2, 163-175.
17. [17] Tipper, D.J. & Strominger, J.L. (1965), Mechanism of action of penicillins : A proposal based on their structural similarity to acyl-D-alanyl-D-alanine. Proc. Natl. Acad. Sci. USA, 54, 1133-1141.
18. [18] Knox, J.R., Moews, P.C. & Frére, J.M. (1996), Molecular evolution of bacterial β-lactam resistance. Chem. Biol., 3, 937-947.
19. [19] Ayliffe, G.I.J. (1963), Ampicillin inactivation and sensitivity of coliform bacilli. J. Gen. Microbiol., 30, 339-348.
20. [20] Richmond, M.H. & Sykes, R.B. (1973), The β-lactamases of gram-negative bacteria and their possible physiological role. Adv. Microb. Physiol., 9, 31-88.
21. [21] Ambler, R.P. (1980), Structure of β-lactamases. Philos. Trans. R. Soc. Land. B Biol. Sci., 289, 321-331.
22. [22] Jaurin, B. & Grundström, T. (1981), ampC Cephalosporinase of Escherichia coli K-12 has a different evolutionary origin from that of β-lactamases of the penicillinase type. Proc. Natl. Acad. Sci. USA, 78, 4897-4901.
23. [23] Oullette, M., Bissonnette, L. & Roy, P.H. (1987), Precise insertion of antibiotic resistance determinants into Tn21-like transposons: Nucleotide sequence of the OXA-1 β-lactamase gene. Proc. Natl. Acad. Sci. USA, 84, 7378-7382.
24. [24] Jap, B.K. & Walian, P.J. (1996), Structure and functional mechanism of porins. Physiol. Rev., 76, 1073-1088.
25. [25] Nüesch, J., Heim, J. & Treichler, H.-J. (1987), The biosynthesis of sulfur-containing β-lactam antibiotics. Ann. Rev. Microbiol., 41, 51-75.
26. [26] Aharonowitz, Y. & Cohen, G. (1992), Penicillin and cephalosporin biosynthetic genes: Structure, organization, regulation, and evolution. Ann. Rev. Microbiol., 46, 461-495.
27. [27] Neu, H.C. (1992), The crisis in antibiotic resistance. Science, 257, 1064-1073.
28. [28] Skurray, R.A. & Firth, N. (1997), Molecular evolution of multiply-antibiotic-resistant staphylococci. in "Antibiotic resistance: Origins, evolution, selection and spread" (D.J. Chadwick & J. Goode) (pp. 167-191). Ciba Foundation Symposium 207, Wiley, Chichester.
29. [29] Hiramatsu, K. (1995), Molecular evolution of MRSA. Microbiol. Immunol., 39, 531-543.
30. [30] Doran, J.L., Leskiw, B K., Aippersbach, S. & Jensen, S.E. (1990), Isolation and characterization of a β-laclamase-inhibitory protein from Streptomyces clavuligerus and cloning and analysis of the corresponding gene. J. Bacteriol., 172, 4909-4918.
31. [31] Strynadka, N.C.J., Jensen, S.E., Alzari, P.M. & James, M.N.G. (1996), A potent new mode of β-lactamase inhibition revealed by the 1.7 Å X-ray crystallographic structure of the TEM-1-BLIP complex. Nature Struct. Biol., 3, 290-297.
32. [32] Baggaley, K.H., Brown, A.G. & Schofield, C.J. (1997), Chemistry and biosynthesis of clavulanic acid and other clavams. Nat. Prod. Rep., 14, 309-333.
33. [33] Sutherland, R. (1995), β-Lactam/β-lactamase inhibitor combinations : Development, antibacterial activity and clinical applications. Infection, 23, 191-200.
34. [34] Pratt, R.F. (1992), β-Lactamase: Inhibition, in "The chemistry of β-lactams" (M.I. Page) (pp. 229-271). Blackie Academic & Professional, Glasgow, U.K.
35. [35] Brogden, R.N., Carmine, A., Heel, R.C., Morley, P.A., Speight, T.M. & Avery, G.S. (1981), Amoxicillin/Clavulanic acid : A review of its antibacterial activity, pharmacokinetics and therapeutic use. Drugs, 22, 337-362.
36. [36] Campoli-Richards, D.M. & rogden, R.N. (1987), Sulbactam/Ampicillin: A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use. Drugs, 33, 577-609.
37. [37] Schoonover, L.L., Occhipinti, D.J., Rodvold, K.A. & Danziger, L.H. (1995), Piperacillin/tazobactam: A new β-lactam/β-lactamase inhibitor combination. Ann. Pharmacother., 29, 501-514.
38. [38] Buckley, M.M., Brogden, R.N., Barradel, L.B. & Goa, K.L. (1992), Imipenem/ Cilastatin. A reappraisal of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs, 44, 408-444.
39. [39] Taibi, P. & Mobashery, S. (1995), Mechanism of turnover of imipenem by the TEM β-lactamase revisited. J. Am. Chem. Soc., 117, 7600-7605.
40. [40] Rasmussen, B.A. & Bush, K. (1997), Carbapenem-hydrolyzing β-lactamases. Antimicrob. Agents Chemother., 41, 223-232.
41. [41] Imtiaz, U., Billings, E.M., Knox, J.R. & Mobashery, S. (1994), A structure-based analysis of the inhibition of class A β-lactamases by sulbactam. Biochemistry, 33, 5728-5738.
42. [42] Bulychev, A., Massova, I., Lerner, S. & Mobashery, S. (1995), Penem BRL 42715: An effective inactivator for β-lactamases. J. Am. Chem. Soc., 117, 4797-4801.
43. [43] Imtiaz, U., Billings, E., Knox, J.R., Manavathu, E.K., Lerner, S.A. & Mobashery, S. (1993), Inactivation of class A β-lactamases by clavulanic acid: The role of arginine-244 in a proposed nonconcerted sequence of events. J. Am. Chem. Soc., 115, 4435-4442.
44. [44] Chen, C.C.C., Rahil, J., Pratt, R.F. & Herzberg, O. (1993), Structure of a phosphonate-inhibited β-lactamase. An analog of the tetrahedral transition state-intermediate of β-lactam hydrolysis. J. Mol. Biol., 234, 165-178.
45. [45] Lobkovsky, E., Billings, E.M., Moews, P.C., Rahil, J., Pratt, R.F. & Knox, J.R. (1994), Crystallographic structure of a phosphonate derivative of the Enterobacter cloacae P99 cephalosporinase: mechanistic interpretation of a β-lactamase transition-state analog. Biochemistry, 33, 6762-6772.
46. [46] Maveyraud, L., Pratt, R.F. & Samama, J.P. (1998), Crystal structure of an acylation transition-state analog of the TEM-1 β-lactamase. Mechanistic implications for class A β-lactamases. Biochemistry, 37, 2622-2628.
47. [47] Maveyraud, L., Massova, I., Birck, C., Miyashita, K., Samama, J.-P. & Mobashery, S. (1996), Crystal structure of 6α-hydroxymethylpenicillanate complexed to the TEM-1 β-lactamase from Escherichia coli: Evidence on the mechanism of action of a novel inhibitor designed by a computer-aided process. J. Am. Chem. Soc., 118, 7435-7440.
48. [48] Strynadka, N.C., Adachi, H., Jensen, S.E., Johns, K., Sielecki, A., Betzel, C., Sutoh, K. & James, M.N. (1992), Molecular structure of the acyl-enzyme intermediate in β-lactam hydrolysis. Nature, 359, 700-705.
49. [49] Strynadka, N.C., Martin, R., Jensen, S.E., Gold, M. & Jones, J.B. (1996), Structure-based design of a potent transition state analogue for TEM-1 β-lactamase. Nat. Struct. Biol. 3, 688-695.
50. [50] Matagne, A. & Frére, J.-M. (1995), Contribution of mutant analysis to the understanding of enzyme catalysis : the case of class A β-lactamases. Biochim. Biophys. Acta, 1246, 109-127.
51. [51] Livermore, D.M. (1995), β-Lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev., 8, 557-584.
52. [52] Bret, L., Chaibi, E.B., Chanal-Claris, C., Sirot, D., Labia, R. & Sirot, J. (1997), Inhibitor resistant TEM (IRT) β-lactamases with different substitutions at position 244. Antimicrob. Agents Chemother., 41, 2547-2549.
53. [53] Saves, I., Burlet-Schiltz, O., Swarén, P., Lefévre, F., Masson, J.-M., Promé, J.-C. & Samama, J.-P. (1995), The asparagine to aspartic acid substitution at position 276 of TEM-35 and TEM-36 is involved in the β-lactamase resistance to clavulanic acid. J. Biol. Chem., 270, 18240-18245.
54. [54] Vekulenko, S.B., Geryk, B., Kotra, L.P., Mobashery, S. & Lerner, S. (1998), Selection and characterization of β-lactam/β-lactamase inactivator resistant mutants following PCR mutagenesis of the TEM-1 β-lactamase gene. Antimicrob. Agents Chemother., 42, 1542-1548.
55. [55] Berkowitz, F.E. (1995), Antibiotic resistance in bacteria. South. Med. J., 88, 797-804.
56. [56] Pitout, J.D.D. & Sanders, C.C. (1997), Antimicrobial resistance with focus on β-lactam resistance in gram-negative bacilli. Am. J. Med., 103, 51-59.
57. [57] Luzzaro, F., Pagani, F., Porta, F. & Romero, E. (1995), Extended-spectrum β-lactamases conferring resistance to monobactams and oxyimino-cephalosporins in clinical isolates of Serratia marcescens. J. Chemother., 7, 175-178.
58. [58] Hedberg, M. & Nord, C.E. (1996), β-Lactam resistance in anaerobic bacteria: A review. J. Chemother., 8, 3-16.
59. [59] Turner, P., Edwards, R., Weston, V., Gazis, A., Ispahani, P. & Greenwood, D. (1995), Simultaneous resistance to metronidazole, co-amoxiclav, and imipenem in clinical isolate of Bacteroides fragilis. Lancet, 345, 1275-1277.
60. [60] Howe, R.A., Brown, N.M. & Spencer, R.C. (1996), The new threats of gram-positive pathogens: reemergence of things past. J. Clin. Pathol., 49, 444-449.
61. [61] Cormican, M.G. & Jones, R.N. (1996), Emerging resistance to antimicrobial agents in gram-positive bacteria. Drugs, 51 (suppl. 1), 6-12.